Epidermal growth factor is a biomarker for poor cetuximab response in tongue cancer cells
2016 (English)In: Journal of Oral Pathology & Medicine, ISSN 0904-2512, E-ISSN 1600-0714, Vol. 45, no 1, 9-16 p.Article in journal (Refereed) Published
Background: Epidermal growth factor receptor (EGFR) is a target for treatment in tongue cancer. Here, EGFR ligands were evaluated for their potential uses as predictive biomarkers of cetuximab treatment response.
Methods: In three tongue cancer cell lines the influences of epidermal growth factor (EGF), amphiregulin (AR), and epiregulin (EPR) on tumour cell proliferation and cetuximab response were evaluated by the addition of recombinant human (rh) proteins or the siRNA-mediated downregulation of endogenous ligand production.
Results: EGF or AR downregulation suppressed the proliferation of all investigated cell lines. Furthermore, all cell lines displayed increased cetuximab resistance upon the addition of rhEGF, whereas EGF silencing resulted in an improved cetuximab response in one cell line.
Conclusions: Our data suggest that EGF and AR are critical components of the EGFR signalling network required for full proliferative potential. Moreover, EGF is a potential predictive biomarker of poor cetuximab response and a possible treatment target.
Place, publisher, year, edition, pages
Wiley-Blackwell, 2016. Vol. 45, no 1, 9-16 p.
Head and neck cancer; Tongue cancer; Erbitux; EGFR ligands; treatment response
Cancer and Oncology
IdentifiersURN: urn:nbn:se:liu:diva-100675DOI: 10.1111/jop.12310ISI: 000369990100003OAI: oai:DiVA.org:liu-100675DiVA: diva2:663300
Funding agencies: Foundation of Ake Wiberg; Swedish Cancer Society [2008/552, 2010/545]; County Council of Ostergotland; Linkoping University Hospital; Foundation of Magnus Bergvall; Cancer Foundation of Ostergotland
Vid tiden för disputation förelåg publikationen endast som manuskript2013-11-112013-11-112016-03-21